Laboratory of Heterocyclic Chemistry Natural Product and Reactivity (LR11ES39), Department of Chemistry, Faculty of Science of Monastir, University of Monastir, Monastir 5019, Tunisia.
Department of Chemistry, College of Science, Ha'il University, Ha'il 81451, Saudi Arabia.
Molecules. 2023 Nov 6;28(21):7443. doi: 10.3390/molecules28217443.
In a sustained search for novel potential drug candidates with multispectrum therapeutic application, a series of novel spirooxindoles was designed and synthesized via regioselective three-component reaction between isatin derivatives, 2-phenylglycine and diverse arylidene-imidazolidine-2,4-diones (Hydantoins). The suggested stereochemistry was ascertained by an X-ray diffraction study and NMR spectroscopy. The resulting tetracyclic heterocycles were screened for their in vitro in vivo anti-inflammatory and analgesic activity and for their in vitro antimicrobial potency. In vitro antibacterial screening revealed that several derivatives exhibited remarkable growth inhibition against different targeted microorganisms. All tested compounds showed excellent activity against the strain (93.75 µg/mL ≤ MIC ≤ 375 µg/mL) as compared to the reference drug tetracycline (MIC = 500 µg/mL). Compound bearing a -chlorophenyl group on the pyrrolidine ring exhibited the greatest antifungal potential toward and (MIC values of 23.43 µg/mL and 46.87 µg/mL, respectively) as compared to Amphotericin B (MIC = 31.25 and 62.50 µg/mL, respectively). The target compounds were also tested in vitro against the lipoxygenase-5 (LOX-5) enzyme. Compounds and showed significant inhibitory activity with IC = 1.09 mg/mL and IC = 1.01 mg/mL, respectively, more potent than the parent drug, diclofenac sodium (IC = 1.19 mg/mL). In addition, in vivo evaluation of anti-inflammatory and analgesic activity of these spirooxindoles were assessed through carrageenan-induced paw edema and acetic acid-induced writhing assays, respectively, revealing promising results. In silico molecular docking and predictive ADMET studies for the more active spirocompounds were also carried out.
在寻找具有多谱治疗应用的新型潜在药物候选物的持续研究中,通过区域选择性三组分反应,设计并合成了一系列新型螺噁吲哚,该反应涉及到色胺衍生物、2-苯甘氨酸和各种芳亚甲基-咪唑烷-2,4-二酮(海因二酮)。通过 X 射线衍射研究和 NMR 光谱确定了建议的立体化学。对所得的四环杂环化合物进行了体外抗炎和镇痛活性以及体外抗菌效力的筛选。体外抗菌筛选表明,几种衍生物对不同靶向微生物表现出显著的生长抑制作用。与参考药物四环素(MIC = 500 µg/mL)相比,所有测试化合物对 菌株均表现出极好的活性(93.75 µg/mL ≤ MIC ≤ 375 µg/mL)。在吡咯烷环上带有 -氯苯基的化合物 对 和 (MIC 值分别为 23.43 µg/mL 和 46.87 µg/mL)表现出最大的抗真菌潜力,而两性霉素 B 的 MIC 值分别为 31.25 和 62.50 µg/mL)。目标化合物也在体外针对脂氧合酶-5(LOX-5)酶进行了测试。化合物 和 表现出显著的抑制活性,IC = 1.09 mg/mL 和 IC = 1.01 mg/mL,比母体药物双氯芬酸钠(IC = 1.19 mg/mL)更有效。此外,通过角叉菜胶诱导的爪肿胀和醋酸诱导的扭体试验,评估了这些螺噁吲哚的体内抗炎和镇痛活性,结果令人鼓舞。还对更活跃的螺杂化合物进行了计算机分子对接和预测 ADMET 研究。